Abstract
Inhaled medications are the mainstay of therapy for many pediatric pulmonary diseases. Device and delivery technique selection is key to improving lung deposition of inhaled drugs. This paper will review the subject in relationship to several pediatric clinical situations: acute pediatric asthma, transnasal aerosol delivery, delivery through tracheostomies, and delivery during noninvasive and invasive mechanical ventilation. This review will focus on the pediatric age group and will not include neonates.
- nasal cannula
- noninvasive ventilation
- NIV
- nebulizer
- metered dose inhaler
- nasal delivery
- children
- valved holding chamber
- HFNC
- albuterol
- mechanical ventilation
Footnotes
- Correspondence: Ariel Berlinski MD, 1 Children's Way, Slot 512-17, Little Rock, AR 72202. E-mail: berlinskiariel{at}uams.edu.
Dr Berlinski has disclosed relationships with Vertex, Cempra, AbbVie, Allergan, Genentech, Janssen, Gilead, Teva, Philips, Novartis, National Institutes of Health, and Therapeutic Development Network. Dr Berlinski is a Science Advisor to the Device Human Factors Subgroup of the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS).
Dr Berlinski presented a version of this paper at the 55th Respiratory Care Journal Conference, “Pediatric Respiratory Care,” held June 10–11, 2016, in St Petersburg, Florida.
- Copyright © 2017 by Daedalus Enterprises
Jump to section
- Article
- Abstract
- Introduction
- Delivery Device Selection for the Treatment of Acute Pediatric Asthma
- Transnasal Aerosol Delivery in Pediatric Patients
- Delivery Device Selection for Spontaneously Breathing Tracheostomized Children
- Delivery Device Selection for Pediatric Patients Receiving NIV
- Delivery Device Selection for Mechanically Ventilated Pediatric Patients
- Summary
- Discussion
- Footnotes
- References
- REFERENCE
- Figures & Data
- Info & Metrics
- References